Solid Phase Synthesis of Liraglutide via Fmoc Resin Coupling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing liraglutide, a glucagon-like peptide-1 receptor agonist, are costly and unsuitable for large-scale production due to complex biological techniques and inefficient solid-liquid phase synthesis processes that generate numerous impurities and waste, requiring multiple purification steps and acetonitrile.
Innovation Solution
A solid phase synthesis method involving Fmoc-protected glycine coupling to a resin support, sequential coupling of amino acids with side-chain protection, removal of protective groups, and purification using reverse-phase HPLC, which simplifies operations, reduces waste, and enhances yield.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If solid-liquid phase synthesis is used with reverse-phase HPLC purification, then liraglutide can be produced, but the process generates numerous impurities and waste requiring multiple purification steps
Solution Approach 1:
The patent changes the physical state parameter from solid-liquid phase synthesis to solid phase synthesis, where the growing peptide chain remains attached to solid resin support throughout the synthesis. This fundamental parameter change enables impurities to remain in solution and be easily washed away, eliminating the need for complex reverse-phase HPLC purification steps and dramatically reducing waste liquid generation.
Solution Approach 2:
The synthesis process is segmented into discrete coupling cycles where individual amino acids are added sequentially to the resin-bound peptide chain. Each coupling step is followed by washing to remove excess reagents and by-products, effectively segmenting the purification process from the synthesis process itself. This segmentation allows for continuous removal of impurities without requiring final HPLC purification.
2Productivity
If biological methods such as genetic engineering are used, then liraglutide can be produced, but the techniques are complex and cost is high
Solution Approach 1:
The patent replaces complex biological systems (genetic engineering, cell culture, fermentation) with a simpler chemical system based on solid phase peptide synthesis. The mechanical/chemical process uses standardized coupling reagents and protecting group chemistry on solid resin supports, eliminating the need for complex biological infrastructure while maintaining scalability for large-scale production.
Solution Approach 2:
The patent employs disposable solid resin supports that can be loaded with amino acids, used for synthesis, and then discarded after cleavage of the final product. This approach eliminates the need for expensive, complex biological systems and extensive purification infrastructure, as the resin-bound synthesis inherently provides purification through simple washing steps.
3Ease of operation
If N-terminal of GLP-1(7-37)-OH is not protected and protective groups for side chains are all removed, then reaction with Nα-alkanoyl-Glu(ONSu)-OtBu can proceed, but a great amount of impurities is generated
Solution Approach 1:
The patent applies preliminary protection of side chain functional groups with orthogonal protecting groups before coupling reactions. This preliminary action prevents unwanted side reactions during synthesis, and the protecting groups are strategically removed only when needed, maintaining manufacturing precision while keeping operation steps manageable through systematic deprotection protocols.
Solution Approach 2:
The patent uses orthogonal protecting groups as intermediaries that temporarily mask reactive side chain functionalities during synthesis. These protecting group intermediaries allow the N-terminal and side chains to remain protected during coupling reactions, preventing impurity formation, and can be selectively removed later without affecting the main peptide backbone synthesis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method results in a more efficient, cost-effective, and environmentally friendly process with shorter synthesis cycles, less by-product, and higher yield, making it suitable for large-scale production of liraglutide.
Implementation Method 1
Fmoc-Gly-resin is obtained by coupling N-terminal Fmoc-protected glycine (Fmoc-Gly-OH) to a resin solid-phase support
Implementation Method 2
liraglutide is finally obtained by purification and lyophilizing
Implementation Method 3
liraglutide is finally obtained by purification and lyophilizing
Data Source
Figure 1
AI summary
Provided is a method for solid phase synthesis of liraglutide, comprising the following steps: A), Fmoc-Gly-resin being obtained by coupling resin solid phase carrier with glycine with N-end protected by Fmoc(Fmoc-Gly-OH) in the presence of activator system; B) according to the peptide sequence of the main chain of liraglutide, successively coupling with amino acids with N-ends protected by Fmoc and protected side chains by the method for solid phase synthesis, wherein lysine employs Fmoc-Lys(Alloc)-OH; C) removing the protective group, Alloc, from the side chain of lysine; D) couplilng the side chain of lysine with Palmitoyl-Glu-Offiu by the method for solid phase synthesis; E) cleavage, removing protection groups and resin to obtain crude liraglutide; F) purifying and lyophilizing to obtain liraglutide.